Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

AACR 2009: Genetic variants in microRNA processing pathway genes and ovarian cancer risk

AACR 2009

18 - 22 Apr 2009

Published: 30 Apr 2009

Views: 16524

Rating:

Save

Professor Xifeng Wu - Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, USA

Xifeng Wu, M.D., Ph.D., professor, department of epidemiology, University of Texas M.D. Anderson Cancer Center, presenting at AACR 2009, Denver: Genetic Variants in MicroRNA Processing Pathway Genes and Ovarian Cancer Risk

Related Videos

Novel therapies and combinations in ovarian cancer

Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France

Novel therapies and combinations in ovarian cancer ( Dr Alexandria Leary - Institute Gustave Roussy, Villejuif, France )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

First-line chemotherapy with atezolizumab and bevacizumab significantly...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Atezolizumab with platinum-based CT and niraparib show no improvement in...

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

More from ecancer